• Time to progression [ Designated as safety issue: No ]
• Toxicity as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]
• Pharmacokinetics [ Designated as safety issue: No ]

• Time to progression
• Toxicity as assessed by NCI CTCAE v3.0
• Pharmacokinetics

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with docetaxel in treating patients who have recurrent osteosarcoma (closed to accrual as of 12/21/06), recurrent Ewing's sarcoma, or unresectable or locally recurrent chondrosarcoma.

OBJECTIVES:

Primary

• Determine the objective response rate in patients with recurrent osteosarcoma (closed to accrual as of 12/21/06) or Ewing's sarcoma or unresectable or locally recurrent chondrosarcoma treated with sequential gemcitabine and docetaxel.

Secondary

• Determine the time to progression in patients treated with this regimen.
• Assess the toxicity of this regimen in these patients.
• Compare the pharmacokinetics of this regimen vs gemcitabine alone in these patients.
• Obtain tumor samples for cRNA microarray analysis of gene expression and development of cell lines and xenotransplantation models.

OUTLINE: This is a nonrandomized, multicenter study.

Patients are stratified according to diagnosis (recurrent osteosarcoma [closed to accrual as of 12/21/06] vs recurrent Ewing's sarcoma vs unresectable or locally recurrent chondrosarcoma).

Patients receive gemcitabine IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 9 and continuing until blood counts recover. Patients may receive pegfilgrastim SC on day 9 (once per course) as an alternative to G-CSF. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 1 year.

PROJECTED ACCRUAL: A maximum of 120 patients (40 per stratum) will be accrued for this study within 17-24 months.

• Biological: filgrastim
• Biological: pegfilgrastim
• Drug: docetaxel
• Drug: gemcitabine hydrochloride

DISEASE CHARACTERISTICS:

• Histologically confirmed* diagnosis of 1 of the following:

  • Recurrent high-grade osteosarcoma (closed to accrual as of 12/21/06) or Ewing's sarcoma

    • Progressive disease after standard therapy
    • Received no more than 2 additional salvage regimens

  • Chondrosarcoma

    • Unresectable OR locally recurrent and unable to be completely resected NOTE: *Biopsy required for isolated pulmonary recurrences

• Measurable disease

  • At least 1 unidimensionally measurable lesion by medical imaging techniques
  • Ascites, pleural effusions, and bone marrow disease are not considered measurable disease

PATIENT CHARACTERISTICS:

Age

• 4 and over

Performance status

• ECOG 0-2 (≥ 18 years of age)
• Karnofsky 50-100% (11-17 years of age)
• Lansky 50-100% (≤ 10 years of age)

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3 (transfusion independent)
• Hemoglobin ≥ 8.0 g/dL (transfusion allowed)

Hepatic

• Bilirubin ≤ upper limit of normal (ULN) (except for patients with Gilbert's syndrome)
• ALT ≤ 2.5 times ULN

Renal

• Creatinine clearance or radioisotope glomerular filtration rate > 70 mL/min/1.73 m^2 OR

• Serum creatinine ≤ ULN for age:

  • Ages 5 and under ≤ 0.8 mg/dL
  • Ages 6 to 10 ≤ 1.0 mg/dL
  • Ages 11 to 15 ≤ 1.2 mg/dL
  • Ages 16 to 18 ≤ 1.5 mg/dL

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• Sensory or motor neuropathy due to prior chemotherapy ≤ grade 1
• Sensory or motor neuropathy due to prior surgery or tumor involvement ≤ grade 2 AND stable or improving
• No active or uncontrolled infection
• No known hypersensitivity reaction to docetaxel or other polysorbate 80-formulated agents

PRIOR CONCURRENT THERAPY:

Biologic therapy

• At least 72 hours since prior filgrastim (G-CSF)
• No prior allogeneic transplantation
• No concurrent immunotherapy

Chemotherapy

• At least 2 weeks since prior myelosuppressive therapy
• At least 6 months since prior myeloablative therapy
• No prior gemcitabine
• No prior taxanes
• No other concurrent chemotherapy

Endocrine therapy

• Concurrent hormonal therapy allowed

Radiotherapy

• At least 6 weeks since prior local radiotherapy
• At least 4 months since prior extensive radiotherapy to more than 50% of the pelvis
• At least 4 months since prior cranial spinal radiotherapy
• At least 6 months since prior total body irradiation
• No concurrent radiotherapy

Surgery

• No concurrent surgery

Other

• Recovered from all prior therapy
• No other concurrent investigational anticancer therapy